Today: October 17, 2018, 11:30 pm
  
Health

NEGTEC launches Crowdfunding Portal promoting Regenerative Medicine

NEGTEC launches Crowdfunding Portal promoting Regenerative Medicine
PR-Inside.com: 2018-09-03 13:17:57
Dream-Kicker.com to offer donation-based, cryptocurrency support for cutting-edge regenerative medicine and medical equipment

TOKYO, Sept 3, 2018 - (ACN Newswire) - NEGTEC, originator of the Sakura Bloom (SKB) cryptocurrency project, has announced a new donation-based crowdfunding service and SKB-based web portal to promote the introduction of cutting-edge regenerative medicine and medical equipment to hospitals.


The portal, Dream-Kicker.com, will be used to fund the purchase of regenerative medical equipment using CD34+ cells, and provide support for the introduction of the regenerative medicine to medical institutions and hospitals. Donate SKBs to the designated currency address. When SKBs reach the equivalent price of a device, the SKBs will be donated to a medical institution where CD34+ equipment is scheduled to be installed. The medical institution can then convert the donated SKBs into legal currency at a crypto exchange and purchase the CD34+ medical device from a medical device supplier.

NEGTEC, in its own effort to promote the introduction of regenerative medicine, will donate a CliniMACS device, a Miltenyi Biotec product used in regenerative medicine, to the Ojima Ekimae Clinic in Koto-ku, Tokyo. NEGTEC is hoping to introduce more than 50 of these devices in future via the promotion of its donation-based crowdfunding website.

NEGTEC will continue to support blockchain technology and the paradigm shift from smart contract technology and other future-oriented systems as advocated by the Ministry of Health, Labour and Welfare (MHLW), and provide similar promotional measures in the future.

Web Links:

- dream-kicker.com

- dream-kicker.com/projects/001/

- www.skb-coin.jp/en/

Sakura Bloom (SKB) - NEGTEC Press Conference, Aug 30, 2018:

- www.youtube.com/watch?v=iZiUTaS5ASM

Sakura Bloom (SKB) - Slide Presentation, Aug 29, 2018:

- www.acnnewswire.com/clientreports/598/SKB_180829_Slide_ENG.pdf

For inquiries please contact:

Mr. Kuniyasu, Mr. Ohara, NEGTEC Co., Ltd., T: +81-3-6453-8952, E: info@skb-coin.jp

CD34+ cell therapies

CD34+ cells are undifferentiated cells found in bone marrow and blood. Regenerative medicine using these cells is an effective treatment for critical limb ischemia (CLI) due to a hardening of the lower limb arteries triggered by diabetes or aging, and for non-union fractures. Regenerative techniques using CD34+ cell therapies are eligible for SAKIGAKE Designation under the Ministry of Health, Labour and Welfare

SAKIGAKE Designation

SAKIGAKE shortens pre-market review periods for certain new medical products, aiming to accelerate clinical trials and approval procedures. In Japan, where screening periods for drug candidates are long, Designation was established to shorten the screening period and broaden the treatment options for patients suffering from life-threatening diseases.

CliniMACS Systems

CliniMACS is a device used to extract CD34+ cells from bone marrow and blood when practicing regenerative medicine.

Press Information


Published by
ACN Newswire
+65 6304 8926
e-mail
www.acnnewswire.com



# 441 Words
Related Articles
More From The Author
DOCOMO selects IOTW to develop Micro-Mining for [..]
AnApp Blockchain Technologies Ltd ( AnApp ), the IoT blockchain developer behind IOTW, a new cryptocurrency for IoT applications, is [..]
ETRI showcases Consumer Electronic Technologies of the [..]
Korea's ETRI will present some of its innovative advancements this week at Internationale Funkausstellung (IFA), the world's largest [..]
Tonghai Financial Announces 2018 Interim Results
The first interim results after the Group expanded the core capital with profit and revenue growth After tax profit of [..]
Legend Holdings' 1H 2018 Net Profit Rises [..]
- Continuing to Achieve Strategic Goals and Steady Growth of Overall Value HONG KONG, Aug 29, 2018 - (ACN Newswire) [..]
Avi-Tech ended FY2018 with revenue of S$35.7 [..]
- Proposed final dividend of 1.0 cent per share and a special dividend of 0.3 cents per share - Burn-In [..]
 
More From Health
NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI [..]
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that its subsidiary, Shanghai based [..]
NSAV ANNOUNCES AGREEMENT TO ACQUIRE MAJOR STAKE [..]
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that the Company has acquired a [..]
Drug Abuse Treatment Market to Surpass US$ [..]
(EMAILWIRE.COM, August 06, 2018 ) Global Drug Abuse Treatment Market, by Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, [..]
Nurse Staffing Agency Website Focuses on Services; [..]
Elkhart, IN; August 1, 2018 – Excellent Nursing Services, Inc. (ENS) has announced the launch of the agency’s website highlighting [..]
Primary Sclerosing Cholangitis Market to Reach US$ [..]
(EMAILWIRE.COM, July 30, 2018 ) Global Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.